骨髓细胞特异性STING-YBX1相互作用缓解深静脉血栓症中的凝血
Zhiye Guo1,2, Xiaolong Du3, Chunlei Xing4
1Key Laboratory of Cardiovascular and Cerebrovascular Medicine, Nanjing Medical University, China (Z.G., Z.S., D.X., S.L.).
Circulation research
|August 5, 2025
概括
髓状细胞的STING信号驱动深静脉血栓 (DVT) 炎症. 抑制STING,特别是C-ST16,可以减少血栓形成和炎症,为DVT提供潜在的新疗法.
科学领域:
- 免疫学 免疫学 免疫学
- 心血管生物学 心血管生物学
- 分子医学是分子医学.
背景情况:
- 深静脉血栓症 (DVT) 是心血管死亡的主要原因,其特点是血栓形成和炎症.
- STING (干扰素基因刺激器) 信号通路在DVT病变发生过程中的作用尚不清楚.
- 众所周知,STING在各种疾病中调解炎症反应,但其在DVT中的具体参与需要阐明.
研究的目的:
- 研究骨髓细胞内在的STING信号在深静脉血栓症 (DVT) 的进展中的作用.
- 评估STING抑制剂的治疗潜力,包括一种新型合成,用于管理DVT.
- 在DVT的背景下,探索STING和Y盒结合蛋白1 (YBX1) 之间的相互作用.
主要方法:
- 利用DVT的小鼠模型来研究STING抑制的影响.
- 采用STING抑制剂和骨髓细胞特异性STING的遗传枯竭来评估血栓形成.
- 进行了生物化学分析,以调查STING-YBX1相互作用,并测试了合成 (C-ST16) 的治疗疗效.
主要成果:
- 骨髓细胞特异性STING信号被确定为DVT进展的关键驱动因素.
- 在小鼠DVT模型中,STING抑制显著降低了血栓形成.
- 观察到STING和YBX1之间的直接相互作用,导致核转位和血栓性炎症增加. C-ST16有效地减少了血栓和炎症,没有毒性.
结论:
- 骨髓细胞特异性STING-YBX1信号传递极大地推动了DVT进展中的炎症.
- 刺痛抑制剂,特别是合成C-ST16,显示出作为对DVT的治疗策略的希望.
- 向抑制STING为开发针对血栓性疾病的抗炎疗法提供了新的见解.
相关概念视频
01:17Intracellular Signaling Affects Focal Adhesions
2.8K
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...
2.8K
01:30Venous Thrombosis I: Introduction
41
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
41
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
36
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
36
01:29Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
01:24Regulation of Angiogenesis and Blood Supply
2.7K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.7K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
9.2K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
9.2K